Cystatin C protein
Cystatin 3, CST3
Human cystatin C (or cystatin 3), which is composed of 120 amino acid residues, belongs to the cystatins superfamilly that inactivates lysosomal cysteine proteinases. As a strongly cationic and low-molecular weight (13.4 kDa) protein, it is almost freely filtered across the glomerular membrane, and is mainly used as a biomarker of kidney function. A growing body of evidence suggests that cystatin C is a more reliable biomarker of glomerular filtration rate than creatinine [1-3].
In addition to kidney disease, altered serum levels of cystatin C are associated with several types of cardiovascular disease, including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome [4-7]. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease [8, 9]. Furthermore, Cystatin C has also been investigated as a prognostic marker in several forms of cancer [10-12].
Expressed in E.Coli. N-terminal 6xHis-tag and TEV cleavage site
Recombinant antigen for research use or manufacturing only.
Solution in PBS.
Standard ELISA test, Western blotting
QUALITY CONTROL TEST
BCA to determine quantity of the protein.
SDS-PAGE to determine purity of the protein.
Store at –20°C. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.
 Stevens LA, Coresh J, Schmid CH, et al. (2008) Am J Kidney Dis. 51:395–406.
 Dharnidharka VR, Kwon C, Stevens G. (2002) Am. J. Kidney Dis. 40 (2): 221–6.
 Hermida J, Tutor JC. (2006) Ther Drug Monit. 28 (3): 326–31.
 Zethelius B, Berglund L, Sundström J, et al. (2008) N. Engl. J. Med. 358 (20): 2107–16.
 Ix JH, Shlipak MG, Chertow GM, Whooley MA. (2007) Circulation 115 (2): 173–9.
 Deo R, Fyr CL, Fried LF, et al. (January 2008) Am. Heart J. 155 (1): 62–8.
 Servais A, Giral P, Bernard M, et al. (2008) Am. J. Med. 121 (5): 426–32.
Mi W, Pawlik M, Sastre M, et al. (2007) Nat. Genet. 39 (12): 1440–2.
 Kaeser SA, Herzig MC, Coomaraswamy J, et al. (2007) Nat. Genet. 39 (12): 1437–9.
 Zurdel J, Finckh U, Menzer G, et al. (2002) Br J Ophthalmol 86 (2): 214–9.
 Strojan P, Oblak I, Svetic B, et al. (2004) Br. J. Cancer 90 (10): 1961–8.
 Kos J, Krasovec M, Cimerman N, et al. (2000) Clin. Cancer Res. 6 (2): 505–11.